Dual blockade of the human epidermal growth factor receptor 2 (HER2) with trastuzumab and pertuzumab is the preferred option for neoadjuvant systemic therapy (NST) against node‐positive, HER2‐positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.